Biotechnology News and Research

RSS

Automated insulin pump delivery can reduce hypoglycemia in individuals with type 1 diabetes

An automated on/off feature built into insulin pump systems can suspend insulin delivery when it detects low blood glucose levels (via continuous glucose monitoring), significantly reducing the severity and duration of hypoglycemia in individuals with type 1 diabetes, according to a study published in Diabetes Technology & Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc.

10 Feb 2012

New cERD method can detect RNAi activity in biological fluids

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that its scientists have discovered a novel method for monitoring RNAi activity in blood samples, representing a potential major advance for future development of RNAi therapeutics, other therapeutic modalities, and diagnostics.

10 Feb 2012

Single fibronectin injection can prevent chronic pain development after SCI

Chronic neuropathic pain following a spinal cord injury is common and very difficult to treat, but a new therapeutic strategy requiring a one-time injection into the spinal column has potential to improve patient outcomes.

9 Feb 2012

BGI and VIB's genomics meeting to take place on Feb. 15

Both organizations are already collaborating on several projects, including the mapping of the genomes of more than 1,000 species of gut bacteria, compiled from 577 billion base pairs of sequence data. The leading scientific journal Science selected this work as one of the scientific breakthroughs of 2011. Large-scale genome sequencing is becoming ever more important in life sciences, healthcare and agricultural research.

9 Feb 2012

Mary Ann Liebert to launch BioResearch Open Access in March

BioResearch Open Access, a new bimonthly peer-reviewed open access journal, will launch in March 2012 by Mary Ann Liebert, Inc., publishers.

9 Feb 2012

BioMimetic to launch new bone graft substitute product line at AAOS meeting

BioMimetic Therapeutics, Inc. today announced it will introduce Augmatrix Biocomposite Bone Graft, a new bone graft substitute product line, to surgeons and distributors at its exhibit booth during the American Academy of Orthopedic Surgeons (AAOS) meeting this week in San Francisco, CA.

8 Feb 2012

Positive emotional experience induces people to visit social networking sites

People visit social networking sites such as Facebook for many reasons, including the positive emotional experience that people enjoy and want to repeat, according to an article in Cyberpsychology, Behavior, and Social Networking, a peer-reviewed journal published by Mary Ann Liebert, Inc..

8 Feb 2012

MRI techniques can measure changes in microstructural properties of white matter

Innovative magnetic resonance imaging (MRI) techniques that can measure changes in the microstructure of the white matter likely to affect brain function and the ability of different regions of the brain to communicate are presented in an article in the groundbreaking new neuroscience journal Brain Connectivity, a bimonthly peer-reviewed publication from Mary Ann Liebert, Inc.

8 Feb 2012

Scientists reveal how psychostimulant drugs work to control hyperactivity

It has long been known that psychostimulant drugs have the paradoxical effect of reducing hyperactivity. [Psychostimulant drugs include methylphenidate - known by the trade names Ritalin, Concerta, and Methylin - and methamphetamine]. Since the mid-1950s, millions of children and adults have been prescribed stimulant medications to control attention deficit hyperactivity disorder.

8 Feb 2012

Elan fourth quarter total revenue increases 18% to $271.0 million

Elan Corporation, plc today reported its fourth quarter and full-year 2011 financial results.

8 Feb 2012

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Biologics License Application for pertuzumab and granted Priority Review.

8 Feb 2012

Alexion acquires Enobia Pharma

Alexion Pharmaceuticals, Inc. today announced that the Company has completed its previously announced acquisition of 100% of the capital stock of Enobia Pharma Corp., a private biopharmaceutical company focused on the development of therapies to treat patients with ultra-rare and life-threatening genetic metabolic disorders.

7 Feb 2012

Roche’s new breast cancer drug Pertuzumab up for FDA review

U.S. health regulators, the Food and Drugs Administration (FDA) has granted a priority review for an experimental Roche breast cancer drug that in clinical trials added six months to the time before the disease worsened. Pertuzumab approval decision is due by June 8th this year. It could be used with Herceptin in HER2-positive patients. This was announced by Roche Holding AG's Genentech unit on Tuesday.

7 Feb 2012

World’s first 3D printed jaw transplant

In a medical breakthrough, doctors and bio-engineers have collaborated

7 Feb 2012

Vitrolife fourth quarter sales increase 18% to SEK 95 million

Vitrolife AB: Fourth quarter - Sales increased by 19 percent in local currency. Sales were the highest ever for a single quarter and amounted to SEK 95 (81) million, corresponding to an increase of 18 percent in SEK.

7 Feb 2012

Low-dose MNC hUCB therapy effective in ALS-modeled mice

Repeated, low-dose injections of mononuclear cells derived from human umbilical cord blood have been found effective in protecting motor neuron cells, delaying disease progression and increasing lifespan for mice modeling amyotrophic lateral sclerosis, or ALS, also referred to as Lou Gehrig's disease, report University of South Florida researchers and colleagues from Saneron CCEL Therapeutics, Inc., and the Ribeirao Preto School of Medicine at the University of Sao Paulo, Brazil.

7 Feb 2012

Positive data from Chimerix CMX001 Phase 2 study on CMV disease

Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.

6 Feb 2012

Watson, Acorda partner to introduce tizanidine hydrochloride capsules

Acorda Therapeutics, Inc. today announced that the Company has partnered with Watson Pharma, Inc., a subsidiary of Watson Pharmaceuticals, Inc. to introduce tizanidine hydrochloride capsules, an authorized generic version of ZANAFLEX CAPSULES (tizanidine hydrochloride).

6 Feb 2012

Positive results from Chimerix CMX001 study for CMV in hematopoietic stem cell transplant recipients

6 Feb 2012

SDIX, BD enter collaboration for development of microbiology detection solution

SDIX, a leading provider of biotechnology-based products and services for a broad range of life science, biotechnology, diagnostic and food safety applications, and BD Diagnostics, a segment of BD, a leading global medical technology company, today announced the signing of a comprehensive agreement whereby the two companies will collaborate in the development of a microbiology detection solution.

From BD (Becton, Dickinson and Company) 6 Feb 2012